Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points We’re updating our forecast for HXL for the first time post 4Q earnings, and we’re reiterating our Overweight rating on the shares. Our target price rises USD20 to ......
Key Points Adjusted 2026 run-rate EBITDA (~USD1.04bn) stronger than reported guidance suggests Differentiated nuclear conversion franchise (sole U.S. UF₆ producer) positions Solstice squarely in the U.S. nuclear buildout We rate ......
Key Points Q4 EBITDA and EPS miss on APM and TT segment weakness Q1’26 and FY2026 guidance range midpoint below consensus estimates We rate CC shares Overweight with a 12-month ......
Key Points Q4’25 earnings miss on pricing weakness despite strong TiO2 and zircon volumes Q1’26 guidance below consensus on reduced operating rates (and higher fixed cost absorption). Pricing and volume ......
Key Points Below-consensus Q4’25 EBITDA and EPS. Q1 guidance below consensus primarily on the back of tepid demand Cash generation strong with USD252m operating cash flow and USD160m free cash ......
Key Points Q4’25 EBITDA beat but EPS miss. Q1’26 guidance below consensus EBITDA contraction observed across all three segments (y-o-y). Management commentary cautious We rate HUN shares Overweight with a ......